As the field of epigenetics unfolds, various enzymes have now become important targets for drug screening as cures to various diseases, such as cancer. One such enzyme family is the Histone Deacetylases (HDACs), which modify histones and which in turn helps to regulate gene transcription. Though the mechanism of action is not fully known, it has been shown that inhibition of HDACs results in the overacetylation of histones that in turn can lead to a controlled cell death or apoptosis. As such, several HDAC inhibitors (HDIs) are in phase I or II clinical trials, for example suberoylanilide hydroxamic acid (SAHA; ZOLINZA®, Merck).
Check out one of our POLARstar application notes that describes an HDAC assay: A Fluorescence Based Assay of the Epigenetic Enzyme Histonedeacetylase 1 (HDAC1)